FOS and cancer: Conversely, c-Fos overexpression decreased the proportion of cells at G2/M phase compared with that in NQO1-deficient RKO/pshNQO1 and MDA-MB-231/pCont cancer cells (Figure 4I,J, middle panel), and this effect was mitigated by knockdown of CKS1B (Figure 4I,J, middle panel).